The agency granted clearances for tests for cancer and precancer disorders, infectious respiratory diseases, and risk of sepsis and septic shock, among others.

Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.

H.U. Group Holdings Inc. and its subsidiary Fujirebio have announced the launch of the Lumipulse G sTREM2 assay, a ...

Fujirebio collaborates with Stanford Medicine to advance research and innovation in the field of infectious disease testing: Tokyo, Japan Saturday, June 7, 2025, 13:00 Hrs [IST] F ...

The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose ...

The partners will work together to explore the use of a technology from Fujirebio subsidiary Fluxus in infectious disease.

Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of ...

Fujirebio, líder em inovação em diagnósticos in-vitro, anunciou hoje uma colaboração com a Stanford Medicine (Localização: Palo Alto, Califórnia, EUA) para avançar na pesquisa e inovação no campo de t ...

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLE ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...

Malvern biotechnology company Fujirebio Diagnostics has developed a revolutionary new test to diagnose Alzheimer’s disease, ...

Fujirebio Diagnostics Inc., developer of the first FDA-approved blood test for Alzheimer’s disease, filed a lawsuit seeking a federal court’s ruling that its test doesn’t violate a Quanterix Corp.